BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29278742)

  • 1. Evaluation of the suitability of a Sprague Dawley rat model to assess intravenous iron preparations.
    Span K; Pieters EHE; Brinks V; Hennink WE; Schellekens H
    J Pharmacol Toxicol Methods; 2018; 91():7-17. PubMed ID: 29278742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose.
    Elford P; Bouchard J; Jaillet L; Pearson N; Rogue A; Sabadie C; Forster R
    J Pharmacol Toxicol Methods; 2013; 68(3):374-83. PubMed ID: 23624021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences between original intravenous iron sucrose and iron sucrose similar preparations.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Arzneimittelforschung; 2009; 59(4):176-90. PubMed ID: 19517894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Inflamm Allergy Drug Targets; 2012 Feb; 11(1):66-78. PubMed ID: 22309085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and toxicity of intravenous iron in a mouse model of critical care anemia*.
    Heming N; Lettéron P; Driss F; Millot S; El Benna J; Tourret J; Denamur E; Montravers P; Beaumont C; Lasocki S
    Crit Care Med; 2012 Jul; 40(7):2141-8. PubMed ID: 22564959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator.
    Toblli JE; Cao G; Angerosa M
    Biometals; 2015 Apr; 28(2):279-92. PubMed ID: 25609135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of Magnetic Resonance Imaging for Non-Invasive Assessment of Venofer® Biodistribution in Rats.
    Span K; Pieters EHE; Hennink WE; van der Toorn A; Brinks V; Dijkhuizen RM; van Tilborg GAF
    Pharm Res; 2018 Mar; 35(4):88. PubMed ID: 29520577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous iron sucrose reverses anemia-induced cardiac remodeling, prevents myocardial fibrosis, and improves cardiac function by attenuating oxidative/nitrosative stress and inflammation.
    Toblli JE; Cao G; Rivas C; Giani JF; Dominici FP
    Int J Cardiol; 2016 Jun; 212():84-91. PubMed ID: 27038710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.
    Pai AB
    Ann N Y Acad Sci; 2017 Nov; 1407(1):17-25. PubMed ID: 29027212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of available intravenous iron preparations in hemodialysis.
    Palmer K; Cameron K; Battistella M
    CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized trial of intravenous and oral iron in chronic kidney disease.
    Agarwal R; Kusek JW; Pappas MK
    Kidney Int; 2015 Oct; 88(4):905-14. PubMed ID: 26083656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of early gastrointestinal tract and liver toxicity of the originator iron polymaltose complex (IPC) and an IPC similar preparation in non-anemic rats.
    Toblli JE; Cao G; Angerosa M
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):573-83. PubMed ID: 22578204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is intravenous iron sucrose the treatment of choice for pregnant anemic women?
    Devasenapathy N; Neogi SB; Zodpey S
    J Obstet Gynaecol Res; 2013 Mar; 39(3):619-26. PubMed ID: 23167561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence decision for nanoparticular iron complex drugs for parenteral administration based on their disposition.
    Schnorr J; Fütterer S; Spicher K; Catarinolo M; Schlösser C; Enzmann H; Langguth P
    Regul Toxicol Pharmacol; 2018 Apr; 94():293-298. PubMed ID: 29454888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial.
    Kochhar PK; Kaundal A; Ghosh P
    J Obstet Gynaecol Res; 2013 Feb; 39(2):504-10. PubMed ID: 22925176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
    Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
    J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing preoperative haemoglobin in major orthopaedic surgery using intravenous iron with or without erythropoietin. An epidemiologic study.
    Basora M; Colomina MJ; Tio M; Mora L; Sánchez-Etayo G; Salazar F; Ciércoles E; Paños M; Guerrero E; Berge R
    Rev Esp Anestesiol Reanim; 2015; 62(6):313-21. PubMed ID: 25698609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of intravenous iron in anemia management and transfusion avoidance.
    Auerbach M; Goodnough LT; Picard D; Maniatis A
    Transfusion; 2008 May; 48(5):988-1000. PubMed ID: 18346021
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
    Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
    J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.